Business Wire

AMADIS

29.9.2020 13:57:09 CEST | Business Wire | Press release

Share
Amadis Leverages Nexo Standards to Simplify Global Payment Acceptance

Amadis , a payment software and consulting services provider, today announced a streamlined path for North American and international merchants to migrate to the nexo global payment standard, the most comprehensive set of global payment acceptance protocols on the market today. By integrating nexo’s messaging protocols, standards and specifications into its Arkos universal payments acceptance software, Amadis provides “plug-and-play” universal payment software that enables customers to quickly accept new payment types, independent of equipment, technology or geography.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005023/en/

Amadis has helped a diverse range of banking, retail and transport customers deploy nexo-based applications, enabling customers to future-proof their payment systems, while lowering development time and accelerating time to market. With Amadis’ Arkos product, an EMV middleware that manages all the card acceptance processing, customers can rapidly migrate to nexo and vastly reduce their custom development requirements, enabling companies to substantially reduce time to market, risks and costs for each unique payment solution implementation. Arkos can manage any type of equipment (standalone, PINPads, unattended, mobile) and devices while:

  • Integrating US processing rules (debit network selection; low value payments)
  • Providing central management and reporting
  • Meeting M-TIP, ADVT Pre-certified EMV requirements

“By editing the Amadis Arkos software using nexo protocols, we ensure our clients have the same common interoperable interface and protocol across the globe that breeds innovation at the point of contact,” said Emmanuel Haydont, CEO, and co-founder of Amadis. “By using nexo protocols, we help our customers drastically reduce time to market and cost of ownership, while enabling them to free themselves from unnecessary technical dependencies and provide a pathway that better future-proofs merchants as payments continue to evolve.”

nexo standards is the international association enabling global interoperability in payment acceptance. Its membership is expanding rapidly across continents, with members from several countries including the United States, Canada, China, India, Japan, Russia, and Saudi Arabia, further cementing the global interest in its standards and its truly international reach.

Unlike proprietary solutions that lock companies into using proprietary host interfaces, terminal management systems (TMS), platforms or operating in a certain geography, nexo is an open standard that guarantees multiple interoperabilities: cross border, platform, host, market segment and others. nexo standards enables companies to innovate on top of its specifications and protocols, removing both the significant complexity from the technical integration as well as the implementation challenges companies face as they expand acceptance of new payment types from devices in new markets. The nexo association provides open standards and protocols that guarantee cross-border interoperability.

“Market demand for nexo standards is higher than ever before. In response, active members such as Amadis are making significant progress in their deployment and adoption strategies,” comments Jacques Soussana, Secretary-General at nexo standards. “With the combination of our specifications, protocols, implementation guidelines, collaborative working groups, and testing and certification support, we are providing members with the tools to build and validate their solutions, fast-tracking their path to deployment. The global adoption of nexo standards is fast becoming a reality.”

Amadis’ global customers require payment acceptance solutions that are secure and ensure optimized operations, while allowing for best management of future-proofing needs in the near and long-term. nexo standards is the international association enabling global interoperability in payment acceptance. With the recent global stresses the economy and industries have faced, it has become imperative that solution providers seek out standards such as nexo that allow businesses to operate more efficiently and expand globally.

*EMV ® is a registered trademark in the U.S. and other countries and an unregistered trademark elsewhere. The EMV trademark is owned by EMVCo, LLC

About Amadis

Amadis is a privately-held division of Maxim Integrated. Amadis is a leader in payment software technology, with its software running on more than 10 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment processing options using custom or commercially available technology, independent of hardware or geography. The company brings an elite, experienced software team to the industry and enables solutions for international merchants in over 23 countries. Learn more at www.amadis.ca .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye